Oncology Based In-vivo CRO Market By Model Type (Syngeneic Models, Xenograft Models, Orthotopic Models, Genetically Engineered Models {GEMs}, and Others), By Service Type (Toxicology Testing, Efficacy Testing, Drug Discovery and Development, Pharmacokinetics and Pharmacodynamics (PK/PD), Biomarker Analysis, and Others), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Hematological Malignancies, and Others), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Government and Non-Profit Organizations, and others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Oncology Based In-vivo CRO Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising cancer prevalence increasing demand for preclinical research in oncology drug development

3.2.2. Growing R&D investments by pharmaceutical and biotechnology companies driving market expansion

3.2.3. Advancements in animal models enhancing accuracy and efficiency of preclinical oncology studies

3.3. Key industry pitfalls & challenges

3.3.1. Ethical concerns and regulatory restrictions on animal testing impacting market growth

3.3.2. High costs associated with In-vivo studies limiting accessibility for smaller organizations

3.3.3. Alternative technologies such as In-vitro models, reducing dependency on animal testing

3.4. Market Opportunities

3.4.1. Increasing focus on personalized medicine creating demand for specialized In-vivo CRO services

3.4.2. Emerging markets offering untapped potential for preclinical oncology research outsourcing growth

3.4.3. Collaborations between CROs and pharma companies accelerating drug development processes globally

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Oncology Based In-vivo CRO Market, Model Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Model Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Syngeneic Models

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Xenograft Models

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Orthotopic Models

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Genetically Engineered Models (GEMs)

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Others

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Oncology Based In-vivo CRO Market, Service Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Service Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Toxicology Testing

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Efficacy Testing

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Drug Discovery and Development

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Pharmacokinetics and Pharmacodynamics (PK/PD)

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Biomarker Analysis

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Others

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Oncology Based In-vivo CRO Market, Indication Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Indication, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Lung Cancer

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Breast Cancer

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Colorectal Cancer

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Prostate Cancer

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Hematological Malignancies

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. Others

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Oncology Based In-vivo CRO Market, End-User Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-User, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Pharmaceutical and Biotechnology Companies

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Academic and Research Institutions

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Government and Non-Profit Organizations

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Others

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Oncology Based In-vivo CRO Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Model Type, 2025-2035

8.2.3. North America Market Revenue, By Service Type, 2025-2035

8.2.4. North America Market Revenue, By Indication, 2025-2035

8.2.5. North America Market Revenue, By End-User, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Model Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Service Type, 2025-2035

8.2.6.3. U.S. Market Revenue, By Indication, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-User, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Model Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Service Type, 2025-2035

8.2.7.3. Canada Market Revenue, By Indication, 2025-2035

8.2.7.4. Canada Market Revenue, By End-User, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Model Type, 2025-2035

8.3.3. Europe Market Revenue, By Service Type, 2025-2035

8.3.4. Europe Market Revenue, By Indication, 2025-2035

8.3.5. Europe Market Revenue, By End-User, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Model Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Service Type, 2025-2035

8.3.6.3. Germany Market Revenue, By Indication, 2025-2035

8.3.6.4. Germany Market Revenue, By End-User, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Model Type, 2025-2035

8.3.7.2. France Market Revenue, By Service Type, 2025-2035

8.3.7.3. France Market Revenue, By Indication, 2025-2035

8.3.7.4. France Market Revenue, By End-User, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Model Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Service Type, 2025-2035

8.3.8.3. U.K. Market Revenue, By Indication, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-User, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Model Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Service Type, 2025-2035

8.3.9.3. Italy Market Revenue, By Indication, 2025-2035

8.3.9.4. Italy Market Revenue, By End-User, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Model Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Service Type, 2025-2035

8.3.10.3. Spain Market Revenue, By Indication, 2025-2035

8.3.10.4. Spain Market Revenue, By End-User, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Model Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Service Type, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Indication, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-User, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Model Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Service Type, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Indication, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-User, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Model Type, 2025-2035

8.4.6.2. China Market Revenue, By Service Type, 2025-2035

8.4.6.3. China Market Revenue, By Indication, 2025-2035

8.4.6.4. China Market Revenue, By End-User, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Model Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Service Type, 2025-2035

8.4.7.3. Japan Market Revenue, By Indication, 2025-2035

8.4.7.4. Japan Market Revenue, By End-User, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Model Type, 2025-2035

8.4.8.2. India Market Revenue, By Service Type, 2025-2035

8.4.8.3. India Market Revenue, By Indication, 2025-2035

8.4.8.4. India Market Revenue, By End-User, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Model Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Service Type, 2025-2035

8.4.9.3. Australia Market Revenue, By Indication, 2025-2035

8.4.9.4. Australia Market Revenue, By End-User, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Model Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Service Type, 2025-2035

8.4.10.3. South Korea Market Revenue, By Indication, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-User, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Model Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Service Type, 2025-2035

8.4.11.3. Singapore Market Revenue, By Indication, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-User, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Model Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Service Type, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Indication, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Model Type, 2025-2035

8.5.3. Latin America Market Revenue, By Service Type, 2025-2035

8.5.4. Latin America Market Revenue, By Indication, 2025-2035

8.5.5. Latin America Market Revenue, By End-User, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Model Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Service Type, 2025-2035

8.5.6.3. Brazil Market Revenue, By Indication, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-User, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Model Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Service Type, 2025-2035

8.5.7.3. Argentina Market Revenue, By Indication, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-User, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Model Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Service Type, 2025-2035

8.5.8.3. Mexico Market Revenue, By Indication, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-User, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Model Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Service Type, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Indication, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-User, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Model Type, 2025-2035

8.6.3. MEA Market Revenue, By Service Type, 2025-2035

8.6.4. MEA Market Revenue, By Indication, 2025-2035

8.6.5. MEA Market Revenue, By End-User, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Model Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Service Type, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Indication, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-User, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Model Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Service Type, 2025-2035

8.6.7.3. South Africa Market Revenue, By Indication, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-User, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Model Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Service Type, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Indication, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-User, 2025-2035

9. Company Profile

9.1. Charles River Laboratories

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Labcorp Drug Development

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. ICON plc

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. WuXi AppTec

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Parexel International

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Envigo

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Medpace

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Pharmaron

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Syneos Health

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. IQVIA

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Taconic Biosciences

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Champions Oncology

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Crown Bioscience

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. XenTech

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Horizon Discovery

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis

9.16. InVivo Biosystems

9.16.1. Business Overview

9.16.2. Financial Performance

9.16.3. Product/Service Offerings

9.16.4. Strategies & recent developments

9.16.5. SWOT Analysis

9.17. Oncodesign

9.17.1. Business Overview

9.17.2. Financial Performance

9.17.3. Product/Service Offerings

9.17.4. Strategies & recent developments

9.17.5. SWOT Analysis

9.18. GemPharmatech

9.18.1. Business Overview

9.18.2. Financial Performance

9.18.3. Product/Service Offerings

9.18.4. Strategies & recent developments

9.18.5. SWOT Analysis

9.19. Eurofins Scientific

9.19.1. Business Overview

9.19.2. Financial Performance

9.19.3. Product/Service Offerings

9.19.4. Strategies & recent developments

9.19.5. SWOT Analysis

9.20. Polaris Biotechnology

9.20.1. Business Overview

9.20.2. Financial Performance

9.20.3. Product/Service Offerings

9.20.4. Strategies & recent developments

9.20.5. SWOT Analysis